Published online Feb 16, 2023. doi: 10.12998/wjcc.v11.i5.1077
Peer-review started: September 20, 2022
First decision: November 30, 2022
Revised: December 12, 2022
Accepted: January 19, 2023
Article in press: January 19, 2023
Published online: February 16, 2023
Processing time: 147 Days and 0 Hours
Maple syrup urine disease (MSUD) is an autosomal recessive genetic disorder caused by defects in the catabolism of the branched-chain amino acids (BCAAs). However, the clinical and metabolic screening is limited in identifying all MSUD patients, especially those patients with mild phenotypes or are asymptomatic. This study aims to share the diagnostic experience of an intermediate MSUD case who was missed by metabolic profiling but identified by genetic analysis.
This study reports the diagnostic process of a boy with intermediate MSUD. The proband presented with psychomotor retardation and cerebral lesions on magnetic resonance imaging scans at 8 mo of age. Preliminary clinical and metabolic profiling did not support a specific disease. However, whole exome sequencing and subsequent Sanger sequencing at 1 year and 7 mo of age identified bi-allelic pathogenic variants of the BCKDHB gene, confirming the proband as having MSUD with non-classic mild phenotypes. His clinical and laboratory data were retrospectively analyzed. According to his disease course, he was classified into an intermediate form of MSUD. His management was then changed to BCAAs restriction and metabolic monitoring conforming to MSUD. In addition, genetic counseling and prenatal diagnosis were provided to his parents.
Our work provides diagnostic experience of an intermediate MSUD case, suggesting that a genetic analysis is important for ambiguous cases, and alerts clinicians to avoid missing patients with non-classic mild phenotypes of MSUD.
Core Tip: Clinical and metabolic screening is limited in identifying all patients with maple syrup urine disease (MSUD), especially those patients with mild phenotypes or are asymptomatic. Here we present the diagnostic process of an intermediate MSUD case with a mild phenotype, who was missed by metabolic profiling but identified by genetic analysis. This case suggests that genetic testing could contribute to the identification of non-classic mild MSUD cases and alerts clinicians to avoid missing these patients.